Abstract: An operating method of a vaccine management device of the present invention includes: waiting, by the identification code recognition unit, recognition of an identification code; determining, when a first identification code is recognized in the first waiting step, whether the first identification code is a subject person identification code of a vaccine inoculation subject person; waiting, when the first identification code is the subject person identification code, recognition of a vaccine identification code; determining, when a second identification code is recognized in the second waiting step, whether the second identification code is the vaccine identification code; and transmitting, when the second identification code is the vaccine identification code, data obtained by merging subject person identification information corresponding to the subject person identification code and vaccine identification information corresponding to the vaccine identification code, to a management server.

Abstract: The disclosure relates to biomarkers for predicting a therapeutic response of a patient to an immune therapy. Since gene signatures and markers according to an aspect have an excellent predictive capacity for predicting a patient's therapeutic response to an immune therapy, a patient group predicted to exhibit therapeutic effects may be selected to perform an appropriate treatment, and a patient's suffering and costs may be reduced.

Abstract: Provided are a composition and a kit, each for culturing natural killer cells, and a method of using the same. According to the composition for culturing natural killer cells according to aspect, and a method of culturing natural killer cells using the same, when natural killer cells are cultured in peripheral blood mononuclear cells, they are cultured in a medium including the composition for culturing natural killer cells, the composition including magnetic particles, of which at least one surface is bound with an activating receptor ligand, an inhibitory receptor ligand, a costimulatory receptor ligand, a cytokine, a cytokine receptor, an immune checkpoint ligand, a blocking antibody, or a combination thereof, thereby proliferating natural killer cells in a large quantity and promoting activation or inhibition of natural killer cells, or expansion of natural killer cells. Accordingly, the natural killer cells cultured using the same may be usefully applied to immune cell therapy products.